|Year : 2009 | Volume
| Issue : 2 | Page : 242-244
The steroid benefit in treating complicated haemangioma
Kamal H Saleh
Department of Plastic Surgery, Al Emadi Hospital, Doha, Qatar
|Date of Web Publication||29-Jan-2010|
Kamal H Saleh
Department of Plastic Surgery, Al Emadi Hospital, Doha
Source of Support: None, Conflict of Interest: None
The clinical study included 30 patients with complicated cutaneous haemangioma (ulceration, bleeding, obstruction of anatomical orifices, and interference with function or movement). The patients were studied regarding the age group, sex, site of lesion, size of lesion, and the percentage of regression after treatment with steroid.
The age ranged from three months to six years, there were 20 female patients and 10 male patients.
We used local injection of diluted triamcinolone 4 mg with 5 ml. 0.9% NACI (normal saline), injected through 23-guage syringe under local or general anaesthesia every two weeks for six to eight sessions depending on the severity of the case, followed by a local pressure dressing. We measured the size of the lesion before each session and recorded the regression of the lesion. The patients were followed up for two years. Haemangioma commonly presents in infants and children, most commonly in females, especially in the head and neck and are usually of a small size. It regresses if the treatment is started earlier.
Keywords: Steroid therapy; haemangiomas; diluted steroid
|How to cite this article:|
Saleh KH. The steroid benefit in treating complicated haemangioma. Indian J Plast Surg 2009;42:242-4
| » Introduction|| |
Haemangiomas are immature rests of vasoformative tissue that demonstrate angioblastic proliferation and regression and represent the most common vascular tumour of childhood.  Infantile haemangioma is more common in females, occurs in 10% of the children, usually appears within a few weeks after birth; about 30-90% of cases undergo a characteristic proliferation phase that lasts between 6-12 months. This proliferative period is followed by a stable phase, and finally a period of regression or involution, occurs  usually between the 10-12 years.  Infants with alarming cutaneous haemangioma may be treated medically with a high dose of steroid. However, only two-thirds of these haemangiomas regress or stabilize  and well defined surgery is may be necessary for aesthetic correction at the age of 8-10 years  or to improve sign and symptoms of infantile hemangiomas.  The size of the haemangioma and the age of initiation of the treatment are the most important factors affecting the response to the treatment.  The site of the lesion and the phase of the haemangioma are also factors that affect outcome.  The age of initiation to steroid is usually at 7.5 months and the treatment may continue for as long as five months.  Selection of the type of steroid and the route of administration and dose schedule is guided by clinical experience.  Intralesional injection of steroid is an effective treatment for haemangioma of the head and neck,  with injection pressure routinely exceeding the systemic arterial pressure in capillary haemangiomas. 
| » Material and Methods|| |
Thirty patients with complicated haemangioma (ulceration, bleeding, obstruction of anatomical orifice, and interference with function or movement) of different age groups collected through simple random sampling in outpatient cases were treated with local injection of diluted triamcinolone 4 mg with 5 ml normal saline in multiple sessions, two weeks apart [Figure 1]a,b,c and [Figure 2]a,b. The age of patients ranged from three months to six years; 20 patients were females while 10 were males. We used traditional syringe for injection (23-guage) under local or general anaesthesia, followed by local pressure dressing and repeated the procedure every two weeks for six to eight sessions depending on the severity of case, . The size of the lesion before each session was measured to record the regression of the lesion.
| » Results|| |
Of the 30 patients that visited the outpatient clinic, 20 were females while 10 patients were males.
The age of presentation to the clinic was: 10 patients < one year, 10 patients from one year - < four years, and 10 patients from four years - < six years.
The most common site of haemangioma in these patients was head and neck in about 51%, the second most common site was the trunk (33%), followed by the extremities (13%), and the genitalia (3%).
We found also that 10 patients the size of cutaneous hemangioma was (1-2cm), 8 patients was (2-3cm), 7 patients was (3-4cm),& 5 patients was (4-5cm), as shown in the [Table 1].
After treatment we found that the 60% of the cutaneous haemangiomas regressed in the age group between one-six years old, the regression was seen in about 25% as shown in [Table 2].
We found that only three patients suffered from complication of steroid treatment, moon facies in two and systemic infection in one.
| » Discussion|| |
In 30 patients with cutaneous haemangioma, we found that the most common age group presenting with haemangiomas was that of infants and children (three months - six years). This deduction agrees with the study of Winter et al., who found that 65.3% were infants and children. 
The female to male ratio was 2:1, and is similar to the study of Garzon M who found that haemangiomas occur in females three times more than males. 
Haemangiomas presented in the head and neck region in about 51%, trunk (33%), extremities (13%), and genitalia (3%). This agrees with the study conducted by Mullkin and Glowacki, who found that 60% of haemangiomas are in the head and neck area, 25% in the trunk, and 15% in the extremities. 
Like the Garzon study  we also found that a majority of our haemangiomas, 83.3%, were smaller in size.
After treatment with local steroid the percentage of regression was found to be 60% when we started the treatment in the early period (three months - et al., who found that the age of initiation of treatment is the most important factor affecting the response to treatment. 
| » References|| |
|1.||Akyuz C. Management of cutaneous hemangioma. Pediatr Hematol Oncol 2001;18:47-55. |
|2.||Sadan N. Treatment of infants with high doses of prenisolone. J Pediatr 1996;128:141-6. |
|3.||Winter H, Dräger E, Sterry W. Sclerotherapy in treatment of hemangioma. Dermatol Surg 2000;26:105-8. |
|4.||Leatue Labreze C. Sever hemangioma. Ann Dermatol Venreal 1998;125:174-8. |
|5.||Park EA. Infantile hemangioma. J Korean Med Sci 2001;16:127-9. |
|6.||Mokni M. Pyoderma gangrenous. Hosp Pract 2001;36:40-4. |
|7.||Egbert JE. High injection pressure in capillary hemangioma. Arch Ophthalmol 2001;119:677-83. |
|8.||Buyukpamukeu M. Cutaneous hemangioma. Pediatr Hematol Oncol 2000;16:33-6. |
|9.||Garzon M. Hemangioma update on classification. Cutis 2000;66:325-83. [PUBMED] [FULLTEXT] |
|10.||Bennaceur S. Mucocutaneous hemangioma in children. Rev Stomatol Chir Maxillofac 2000;101:17. |
|11.||Mulkin, Glowacki. Hemangioma and vascular malformation of the head and neck. 1989;34:156-98. |
|12.||Boutros S. Hemangioma of the face. Perspect Plast Surg 2000;14:45. |
[Figure 1], [Figure 2]
[Table 1], [Table 2]